Hepatic Impairment Trial of Obeticholic Acid

Hepatic Impairment Clinical Trial

Official title:

An Open-Label, Single-Dose Trial to Assess the Effects of Hepatic Impairment on the Pharmacokinetics of Obeticholic Acid (OCA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01904539
• Other study ID #: 747-103
• Status: Completed
• Phase: Phase 1
• First received: May 23, 2013
• Last updated: October 23, 2013
• Start date: June 2013
• Est. completion date: October 2013

Study information

• Verified date: October 2013
• Source: Intercept Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a phase 1 study to evaluate the safety of a single 10 mg dose of obeticholic acid (OCA) in healthy volunteers and patients with liver disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Subject Inclusion Criteria All Subjects

• Female and male subjects = 18 years of age

• Subjects will have a minimum body weight of 45 kg or body mass index (BMI)> 18 kg/m2.

• Contraception: Female subjects must be postmenopausal, surgically sterile, or if premenopausal, be prepared to use = 1 effective method of contraception during the trial and until at least 30 days after administration of OCA.

• Subjects must provide written informed consent and agree to comply with the trial protocol.

Subjects with Hepatic Impairment:

• Evidence of hepatic disease

1. Score = 2 on one of the Child-Pugh parameters, or

2. Histological diagnosis of cirrhosis or presence of esophageal varices, or

3. Abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) levels

• Subjects will satisfy the criteria of the modified Child-Pugh classification for hepatic impairment during Screening:

1. Mild hepatic impairment: Class A (Child-Pugh Scores 5-6 points)

2. Moderate hepatic impairment: Class B (Child-Pugh Scores 7-9 points)

3. Severe hepatic impairment: Class C (Child Pugh Scores 10-15 points)

Healthy volunteers:

• Absence of clinically-relevant abnormalities identified by a detailed medical history, full physical examination, 12-lead ECG

• Clinical laboratory tests within the normal reference range

• Subjects must be within ± 10 years of the mean age and within 20% of the mean BMI of the hepatic impaired subjects (Child-Pugh category A, B, and C)

Subject Exclusion Criteria All Subjects

• Positive test for human immunodeficiency virus (HIV)-1 or HIV-2 at screening

• Presence or history of malignancy, with the exception of basal cell carcinoma

• Received an investigational drug, including OCA, within 30 days or t½=5 prior to dosing

• Blood or plasma donation within 30 days prior to dosing

• History of non-compliance to medical regimens, or subjects who are considered to be potentially unreliable

• Presence or history of clinically significant cardiac arrhythmias that may prohibit the subject from participating in the trial

• Female subjects who are pregnant or lactating

• Subjects who have irritable bowel disease or other GI disorders that have the potential to alter drug or bile acid absorption.

• Subjects who have a history of gall bladder removal, gastric bypass or other GI surgery that may affect drug absorption or the enterohepatic circulation.

Subjects with Hepatic Impairment

• History of alcohol or drug abuse 3 months prior to dosing

• In the opinion of the Investigator and medical monitor, fluctuating or rapidly deteriorating hepatic function within the screening period

• In the opinion of the Investigator, any evidence of additional severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or laboratory finding likely to affect the conduct of the trial or interpretation of the data

• Subjects who have a transjugular intrahepatic portosystemic shunt and/or have undergone portacaval shunting

• Subjects with Wilson's disease, alpha-1 antitrypsin deficiency, glycogen storage diseases and galactosemia

• Heavy smoker or use of tobacco or nicotine products

Healthy Volunteers

• Presence of significant uncontrolled disease that will complicate execution of the trial or interfere with the absorption, distribution, metabolism, or excretion of drugs via the gut

• Evidence of chronic or acute liver disease as documented by medical history, physical examination or diagnostic tests that it likely to affect the conduct of the trial or interpretation of the data

• History of and/or current alcohol abuse (defined as consumption of more than 210 mL of alcohol per week; or the equivalent of fourteen 4-oz glasses of wine, or fourteen 12-oz cans/bottles of beer or wine coolers per week) or drug abuse within the prior two years

• Smoke or use tobacco or nicotine products

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Hepatic Impairment
• Liver Diseases

Intervention

Drug:
• obeticholic acid 10 mg
Single dose OCA 10mg in each arm

Locations

Country	Name	City	State
United States	Clinical Pharmacology of Miami, Inc.	Miami	Florida
United States	Orlando Clinical Research Center	Orlando	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Intercept Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak plasma concentration (Cmax) of OCA and conjugates	maximum concentration	Up to 48 hours	No
Primary	Area under the concentration versus time curve from time 0 to the last sampling time with measurable analyte concentration (AUCt) of OCA and conjugates		Post-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 216 hours post-dose	No
Primary	Time to Cmax (Tmax) of OCA and conjugates		Up to 48 hours	No
Primary	Area under the concentration versus time curve from time 0-24 hours with measurable analyte concentration of OCA and conjugates. (AUC 0-24)		24 hours	No
Secondary	Urine concentration of unchanged OCA and conjugates		0, 6, 12, 24, 30 hours	No
Secondary	Amount of OCA and conjugates excretion in urine		-6to 0, 0 to 6, 6 to 12, 12 to 24, and 24 to 30 hours	No
Secondary	Total amount of OCA and conjugates excreted in urine		0 to 30 hours	No
Secondary	Protein Binding		0, 0.75, 1.5, 6, and 24 hours	No